Cancer Blog
- Dr. Robert Nagourney -

Fibrolamellar Cancer Foundation Symposium September 29, 2022

Do The Mutations That Drive Cancer Actually Affect Immunity?

IN HER2 (+) BREAST CANCER, THE MOST WIDELY USED TREATMENT MAY NOT BE THE RIGHT ONE FOR YOU

STAGE IV PANCREATIC CANCER: A GOOD OPTION AFTER FOLFIRINOX?

Stage 4 Triple-Negative Breast Cancer: The Right Treatment May Be At Hand.

Chemosensitivity Testing Must Evolve at All Medical Providers

WHEN THERE’S NO RIGHT ANSWER THERE ARE MANY WRONG ANSWERS

DNA Signatures and Genomics

BREAKTHROUGH IN RECTAL CANCER: ADVANCING IMMUNE THERAPY

PROGRESS IN CHILDHOOD SARCOMA – HIGH-DOSE IFOSFAMIDE

NEW STAGE 4 COLON CANCER DATA

JUST BECAUSE A DRUG WORKS DOESN’T MEAN THEY’LL PAY FOR IT